GlaxoSmithKline (LON:GSK) has been given a GBX 1,340 ($17.92) target price by JPMorgan Chase & Co. in a report issued on Thursday. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective would suggest a potential downside of 1.54% from the company’s current price.
Other equities research analysts have also issued reports about the stock. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,835 ($24.54) price objective on shares of GlaxoSmithKline in a report on Tuesday, September 19th. Jefferies Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, September 6th. reaffirmed a “buy” rating and set a GBX 1,970 ($26.34) price objective on shares of GlaxoSmithKline in a report on Wednesday, September 13th. Liberum Capital cut their price objective on shares of GlaxoSmithKline from GBX 1,900 ($25.40) to GBX 1,760 ($23.53) and set a “buy” rating for the company in a report on Wednesday, October 4th. Finally, Goldman Sachs Group reaffirmed a “buy” rating and set a GBX 1,900 ($25.40) price objective on shares of GlaxoSmithKline in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline has an average rating of “Hold” and an average price target of GBX 1,563.33 ($20.90).
Shares of GlaxoSmithKline (LON:GSK) opened at GBX 1,361 ($18.20) on Thursday. GlaxoSmithKline has a 52-week low of GBX 1,270 ($16.98) and a 52-week high of GBX 1,724.50 ($23.06). The company has a market cap of $67,480.00 and a PE ratio of 2,835.42.
In related news, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.52), for a total value of £262,000 ($350,314.21). Also, insider Simon Dingemans purchased 1,076 shares of the stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average price of GBX 1,527 ($20.42) per share, with a total value of £16,430.52 ($21,968.87). Insiders have bought a total of 1,577 shares of company stock valued at $2,400,086 over the last quarter.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.